Nectar Lifesciences Ltd. (NLL) is a knowledge driven organization which constitutes a vital part of fast growing Indian Pharmaceutical Industry. It has emerged as top ranked organization amongst midsized Pharmaceutical companies in India as per “Fortune Next 500” 2017 & is  among top 40 fore runners of the Bio-Pharmaceutical industry in Asia-Pacific Region as per “Bio-Spectrum Asia Pacific” 2016 besides being one of the top amongst Indian API manufacturers.

The company has transformed itself from being a small Domestic API player to one of the most integrated player in the Global Cephalosporins Industry within Anti Infective Therapeutic segment. It currently has a strong hold of API & Formulation business in many countries of the world with various State of Art manufacturing facilities spread across the States of Punjab and Himachal Pradesh with compliance to global standards of cGMP, Environment Health Safety (EHS) as well as pool of thousands of highly skilled, knowledgeable, competent qualified work force at all levels.

Business area of the company

The company has developed fully integrated sustainable production systems to manufacture high quality Cephalosporin intermediates, - Active Pharmaceuticals ingredients (APIs) and Finished Dosage Formulations (FDF or Formulations) to meet the diverse requirements of its customer base in India and over many countries worldwide.

Nectar Lifesciences Ltd.

Sakar Healthcare Ltd.

MEDICO

Ind-Swift Laboratories Ltd.

Windlas Biotech Ltd.

Lyka Labs Ltd.

Albert David Ltd.

Brooks Laboratories Ltd.

Kilitch Drugs (India) Ltd.

Venus Remedies Ltd.

Lincoln Pharmaceuticals Ltd.

Krebs Biochemicals & Industries Ltd.

Bafna Pharmaceuticals Ltd.

Zota Health Care Ltd.

Mangalam Drugs And Organics Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	447 Cr		EPS	0.1		High	21.65
Stock P/E	156.5		Net Profit Margin	-5.0		Low	21.15

Market Cap	447 Cr	ROE	2.3%
P/E Ratio(TTM)	156.5	EPS(TTM)	1.2
P/B Ratio	0.4	Dividend Yield	0.0%
Industry P/E	63.6	Book Value	47.6
		Face Value	1.0

NECLIFE